VEGFA and early-onset autosomal dominant Alzheimer disease: The main targets of the active compounds are often involved in HIF-1 signaling pathway (hsa04066), VEGF signaling pathway (hsa04370), MAPK signaling pathway (hsa04010), Alzheimer disease (hsa05010) and PI3K-Akt signaling pathway (HSA 04,151).